T0	Participants 80 143	human immunodeficiency virus-infected children and adolescents:
T1	Participants 280 396	nucleoside reverse transcription inhibitor (NRTI)-experienced, human immunodeficiency virus (HIV)-infected children.
T2	Participants 643 770	Forty-one children and youths between 5 months and 21 years with prior NRTI and no prior NNRTI or protease inhibitor experience
T3	Participants 2422 2455	HIV-infected children and adults.